Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX®▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
Retrieved on:
Saturday, June 12, 2021
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Drugs, Health care, Health sciences, Orphan drugs, Daratumumab, Multiple myeloma, Lenalidomide, Bortezomib, Dexamethasone, Janssen Pharmaceuticals, Cilag, Immunomodulatory imide drug, the MAIA Trial, daratumumab, Multiple Myeloma, the Janssen Pharmaceutical Companies of Johnson & Johnson, THE MAIA TRIAL, DARATUMUMAB, MULTIPLE MYELOMA, THE JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON
These results strongly support the use of daratumumab, lenalidomide and dexamethasone as a new standard of care to extend survival and improve clinical outcomes in transplant ineligible patients with newly diagnosed multiple myeloma.
Key Points:
- These results strongly support the use of daratumumab, lenalidomide and dexamethasone as a new standard of care to extend survival and improve clinical outcomes in transplant ineligible patients with newly diagnosed multiple myeloma.
- Janssen Research & Development, LLC, Janssen-Cilag Ltd., Janssen Pharmaceutica NV and Janssen Biotech, Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
- Overall Survival Results With Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Transplant-ineligible Newly Diagnosed Multiple Myeloma: Phase 3 MAIA Study.
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.